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In this study, we confirm the validity of the proposed Hammersmith score,
which identifies three risk categories of patients and establish its strength
on a large group of 128 chronic myeloid leukemia patients treated with
second-generation tyrosine kinase inhibitors (TKIs) after being resistant
to imatinib. Sixty-one patients were identified as good risk group, 27
patients as intermediate risk group, and 40 patients as poor risk group.
The 1-year cumulative incidence of complete cytogenetic response was
73% in good risk patients, 40% in intermediate risk patients, and 22% in
poor risk patients (P 5 0.0001). Event-free survival at 3-year was 89% in
good risk group, 70% in intermediate group, and 54% in poor risk group
(P 5 0.0001); the estimated 3-year progression-free survival was 95% in
good risk category, 93% in intermediate risk category, and 87% in poor
risk category (P 5 0.05). Kaplan–Meier estimated that the 3-year overall
survival was 100% in good risk category, 93% in intermediate risk cate-
gory, and 82% in poor risk category (P 5 0.04). In conclusion, some prog-
nostic factors before starting second-generation TKIs might predict cyto-
genetic response and outcome. The so-called Hammersmith score was
not yet validated in large series of patients: we demonstrated that this
score is able to discriminate patients at high risk of failure and conse-
quent progression before treatment with second-generation TKIs.
Imatinib mesylate is currently the standard of care for patients with Phila-
delphia-positive chronic myeloid leukemia (Ph1 CML), as it has demon-
strated to induce a complete cytogenetic response (CCyR) in up to 90% and
a major molecular response (MMR) in 40–60% of patients [1]. However, the
emergence of imatinib resistance has become a relevant problem, and
BCR-ABL mutations are the most frequent mechanism underlying this phe-
nomenon, together with other not well-known mechanisms of resistance [2].
Multiple strategies have been developed to overcome imatinib resistance,
including drug dose escalation, combined treatments and novel targeted
agents, such as nilotinib and dasatinib [2]. Also with second-generation tyro-
sine kinase inhibitors (28 TKIs), the achievement of CCyR is associated with
long-term survival, and it is extremely important to define as early as possi-
ble the likelihood of response to these drugs [3]. A score aiming at early
identification of CML patients showing sensitivity to 28TKIs was proposed by
the Hammersmith group [4]. The score was created by analyzing 80 patients
and was based on three prognostic factors: previous cytogenetic response
to imatinib, Sokal risk at diagnosis, and recurrent neutropenia during imati-
nib. Aim of our study was to confirm the validity of this score and to estab-
lish its strength on a large group of CML patients resistant to imatinib and
treated with 28TKIs.
TABLE I. Patient Characteristics According to Hammersmith Stratification at 28 TKI Start
Good risk (61 points) Intermediate risk (27 points) Poor risk (40 points)
Age (years, median) 52 56 48
Sex (M/F) 40/21 10/17 19/21
Sokal risk at diagnosis
Low 37 (59%) 10 (37%) 19 (45%)
Intermediate 16 (26%) 9 (33%) 16 (40%)
High 8 (13%) 8 (29%) 5 (12%)
Additional cytogenetic aberrations (ACA) in Ph1 cells 4 – 2
del(9q) – – 1
Baseline mutations 3 (F359V, E255K, D276G) 3 (M351T, F359V, M244V) 5 (E292K, Q288R, Y253H, M351T, F317L)
Type of imatinib resistance
Primary 13 13 8
Acquired 48 14 32
Type of 28 TKI
Nilotinib 18 9 13
Dasatinib 42 18 27
Patients received allogeneic hematopoietic stem cell transplant – 1 4
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Table I shows clinical–biological features of patients at the time of starting
second-generation TKIs. According to Hammersmith criteria of stratification,
we identified 61 patients with good risk, 27 patients with intermediate risk,
and 40 patients with poor risk. Well-balanced clinical features were found
among the three groups, with respect to median age and Sokal’s risk at
diagnosis. Only six patients with additional cytogenetic abnormalities were
detected, four in the good risk category and two in the poor risk group,
whereas only one patient had del(9q) at presentation. Mutational screening
before starting second-generation TKIs was performed in all patients and
three mutations in good risk patients (F359V, D276G, E255K), three in inter-
mediate risk group (M351T, F359V, M244V), and five in poor risk patients
(E292K, Q288R, Y253H, M351T, F317L) were detected. Four patients devel-
oped a T315I mutation during treatment with second-generation TKIs (one
patient in good risk group, one patient in intermediate and two patients in
poor risk group). Primary resistance was the main cause of switch to sec-
ond-generation TKIs in 34 patients (16 patients in good, 16 patients in inter-
mediate, and eight patients in poor risk), whereas acquired resistance was
detected in 94 patients, mostly in the good and poor risk categories. Forty
patients received nilotinib as second line while 87 patients were switched to
dasatinib. The overall rate of CCyR in this series was 57%: the rate of
CCyR obtained with dasatinib was 64% and with nilotinib 55% (P 5 ns).
The absence of differences allowed us to consider a single cohort, although
treated with two different drugs. Table II shows response and outcome of
patients grouped according to Hammersmith score: 1-year probability of
achieving CCyR was 73%, 40%, and 22%, in good, intermediate, and poor
risk groups, respectively (P 5 0.001). We assessed in a landmark analysis
the prognostic weight of cytogenetic response in all the identified categories,
but we did not find a different outcome for patients at high risk with achieve-
ment of MCyR at 12 months. With this score, we also identified a difference
in MMR rate: 52% in good risk category, 28% in intermediate, and 13% in
poor risk categories (P 5 0.001). Statistical differences were found in 3-year
event-free survival (EFS; 89%, 70%, and 54%, respectively) (P 5 0.0001), a
trend of significance in 3-year progression-free survival (PFS) (95%, 93%,
and 87%, P 5 0.05) and in 3-year overall survival (OS) (100%, 93%,
and 82%, respectively, P 5 0.04, Fig. 1). Nine patients died during the fol-
low-up, eight for progression of disease to blast phase and one patient for
unrelated CML cause.
After imatinib failure, the availability of second-generation TKIs has provided
new therapeutic strategies, replacing allogeneic transplantation as second
choice. Nilotinib and dasatinib allowed the achievement of cytogenetic
response in more than 60% of patients, with complete response in about
50%, with estimated EFS and OS being 50–60% and 80–85%, respectively
[3]. From phase II trials with either drugs it appeared that better survival rate
was observed in patients who experienced cytogenetic relapse during imatinib
treatment instead of hematological relapse or primary resistance to imatinib,
after a median follow-up of 2–3 years. An independent analysis outside of
clinical trials was published from MD Anderson Cancer Center, to determine
when patients with incomplete response on second-generation TKIs should
be considered for alternative treatments. The outcome of 113 patients treated
with nilotinib or dasatinib was analyzed: after 12 months, the achievement of
major cytogenetic response displayed a survival advantage compared to
minor cytogenetic response or complete hematologic response only. The
authors suggested that patients with no cytogenetic response at 3 and 6
months should be considered for alternative therapies [5]. Another study by
the same group [6] showed that long-term outcome of patients who failed
imatinib and were treated with second-generation TKI may be predicted by
the in vitro sensitivity of BCR-ABL1 kinase domain mutations. They assessed
that scoring mutation based on in vitro inhibitory concentration of each TKI
mutation can predict long-term clinical outcome. Forty-one patients out of 169
treated with dasatinib and 45 out of 169 treated with nilotinib were found to
have a mutation. Inhibitory concentration values for each TKI mutation were
stratified into high (n 5 42), intermediate (n 5 25), low (T315I, n 5 9), or
unknown sensitivity (n 5 10). Hematologic and cytogenetic response rates
were similar for patients with or without mutations. For patients in chronic
phase (CP), hematologic and cytogenetic responses correlated with mutation
score. A worse EFS and OS were observed in patients with intermediate and
low mutation scores [6]. Hughes et al. [7], to determine whether response to
the second-generation TKIs can be predicted, monitored 155 patients in CP
who were treated with nilotinib (n 5 73) or dasatinib (n 5 82; all treated with
100 mg or more per day, with 76 of these receiving 70 mg twice daily) after
imatinib failure for a median of 18 months (range 3–36 months). They found
that BCR-ABL ratio measured at 3 months was predictive of achievement of
MMR at 24 months. Patients with a BCR-ABL value of 1.0% International
Scale (IS) had an 86% probability of achieving an MMR by 24 months, com-
pared to patients with values of 1–10% IS or >10% IS that had a probability
of MMR of 55% and 4%, respectively [7]. The assessment of prognostic fac-
tors before treatment with second-generation TKIs and the identification of
patients with unfavourable features that may predict failure to second-line ther-
apy remain major current problems. Recently the Hammersmith group identi-
fied three factors that are associated to achievement of CCyR with dasatinib
or nilotinib second-line [4]. Sokal risks at diagnosis, best cytogenetic response
obtained on imatinib, occurrence of neutropenia at any time during imatinib
therapy (which required dose reduction and/or use of growth factor support)
were selected as independent predictor factors of response to second TKIs.
Also the time from detection of imatinib failure to start of second TKI was rec-
ognized as an independent prognostic factor, but was not included in the final
analysis due to the difficulty to have this data in all patients. The devised
score was then validated in a small cohort of 28 Scottish patients. We could
evaluate the score in all consecutive patients treated with second-generation
TKIs, because all patients were followed from diagnosis. Instead, in a recent
publication aimed to identify a prognostic model for prediction of response,
the MD Anderson Cancer Center was not able to test the Hammersmith score
due to the fact that 61% of patients were referred to the center only after ima-
TABLE II. Outcome of Patients Grouped According to Hammersmith Score
Good risk (61 points) Intermediate (27 points) Poor risk (40 points) P
CCyR, 1 year (%) 73 40 22 0.001
MMR (%) 52 28 13 0.001
EFS, 3 year (%) 89 70 54 0.0001
PFS, 3 year (%) 95 93 87 0.05
OS, 3 year (%) 100 93 82 0.04
Death – 2 7 0.03
Blast crisis/events 2/7 2/7 4/7 ns
Figure 1. Overall survival according to Hammersmith stratification. [Color figure
can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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tinib failure and they could not obtain accurate information on Sokal risk at
diagnosis, neutropenia during imatinib therapy, and exact time elapsed from
start imatinib to development of imatinib failure and start of 28 TKI [8]. How-
ever, the authors, who proposed another score based again on clinical fea-
tures, stated that the time from which the patient was taken off imatinib to
second-generation TKIs start was not identified as independent factor for
EFS. Although one of the reason of choice of second-generation TKIs is the
occurrence of mutations at the moment of resistance and the incorporation of
this data may increase the prognostic ability to identify patients with poor out-
come, this information is not easily available or, as in our series, not represen-
tative of all mechanisms of resistance. Our study represents a validation of
the proposed Hammersmith score, and we found that it is easily applicable,
although this implies that an adequate monitoring during imatinib therapy has
been performed. Patients considered at poor risk should be closely monitored
during second-generation TKIs, and young patients with a sibling donor
should be alerted for a possible transplantation as therapeutic option,
whereas patients with no available donor and/or presence of comorbidities
should be candidate to alternative options that need to be investigated.
Methods
Patients were enrolled in this study from seven Italian centers. All were in
CP, resistant to imatinib and then treated with 28 TKIs, nilotinib or dasatinib,
outside of clinical trials or enrolled in phase II and III studies aimed to prove
the safety and efficacy of the drugs in resistant and/or intolerant patients to
imatinib [9,10]. Chronic phase was defined according to WHO definition.
Conventional cytogenetic analysis was performed on bone marrow cells by
G-banding technique and at least 20 metaphases were analyzed on direct
and short-term cultures after 24 hr; analyses were performed every 3–6
months. For molecular investigations, mononuclear cells were isolated from
20 mL peripheral blood after separation on a Ficoll-Hypaque gradient. RNA
extraction, real time-PCR, and real time-quantitative polymerase chain reac-
tion were performed as already described [11]. BCR-ABL1/ABL1 ratio was
measured using RQ-PCR, as previously described, and the results were
referred to IS [12]. For mutational screening, the methodology used for
mutation detection was the following: after RNA extraction and reverse tran-
scription, overlapping fragments covering the entire kinase domain were
generated by nested PCR and screened by denaturing high performance
liquid chromotography. In positive cases, a direct sequencing was per-
formed. Responses to imatinib standard dose were defined according to
European LeukemiaNet recommendations [13]. Failure was considered as
the lack of complete hematologic response at 3 months and of cytogenetic
response at 6 months, the attainment of less than partial cytogenetic
response at 12 months, of less than CCyR at 18 months, or the loss of com-
plete hematologic response, CCyR or acquisition of BCR-ABL mutations
and clonal cytogenetic evolution (abnormalities in Ph1 cells) at any time.
Suboptimal response was defined by the lack of cytogenetic response at 3
months, less than partial cytogenetic response at 6 months, partial cytoge-
netic response at 12 months and less than MMR at 18 months, or mutations
of BCR-ABL or loss of MMR at any time points.
Statistical analysis was carried out using the SPSS software package.
Probabilities of OS, EFS, and PFS were calculated using the Kaplan–Meier
method. PFS was defined as survival without evidence of accelerated or
blastic phase during therapy with second-generation TKIs. EFS was consid-
ered as survival without death from any cause, loss of haematological or
cytogenetic response (major or complete), progression of disease.
The Hammersmith model was calculated by allocating points as described
by Milojkovic et al [4]: (a) CCyR on imatinib, 0 points; 1–94% Ph-positive
metaphases, 1 point; 95% or more Ph-positive metaphases, 3 points; (b)
Sokal risk group: low, 0 points, intermediate or high, 0.5 points; (c) neutro-
penia during imatinib treatment: no neutropenia, 0 points; recurrent episodes
of grade 3–4 neutropenia that required dose reduction, 1 point. Patients
were divided into three categories: good risk, patients with assigned score
of less than 1.5; intermediate risk, patients with score between 1.5 and 2.5;
poor risk, patients with score higher than 2.5 [4].
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